Cisatracurium pharmacodynamics in patients with oculopharyngeal muscular dystrophy

被引:7
作者
Caron, MJ
Girard, F
Girard, DC
Boudreault, D
Brais, B
Nassif, E
Chouinard, P
Ruel, M
Duranceau, A
机构
[1] CHUM, Notre Dame Hosp, Dept Anesthesiol, Montreal, PQ H2L 4M1, Canada
[2] CHUM, Notre Dame Hosp, Dept Med, Montreal, PQ H2L 4M1, Canada
[3] CHUM, Notre Dame Hosp, Dept Surg, Montreal, PQ H2L 4M1, Canada
关键词
D O I
10.1213/01.ANE.0000140783.39597.FD
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The pharmacodynamics of muscle relaxants in patients with oculopharyngeal muscular dystrophy (OPMD) have never been studied. We designed this study to compare the pharmacodynamics of cisatracurium in OPMD patients versus a control group. Forty patients were enrolled: 20 OPMD patients requiring general anesthesia for cricopharyngeal myotomy and 20 age-matched controls undergoing an operation of similar duration and expected blood loss. Anesthesia was standardized, and both groups received a bolus of cisatracurium 0.1 mg/kg. Onset time, time to 10% T1 recovery, and the intervals 10%, 25% and 25%-75% were calculated for both groups. A subgroup analysis was performed in patients with a more severe form of OPMD. Demographic and intraoperative data were similar. Onset time was significantly longer in OPMD patients compared with the control group (4.6 +/- 1.5 min versus 3.4 +/- 1.0 min; P = 0.001). There was no difference in recovery times or indices between groups, regardless of the severity of the disease. In conclusion, there was no difference in the duration of a cisatracurium-induced neuromuscular block between OPMD patients and a control group. A delayed onset of action of the drug may occur.
引用
收藏
页码:393 / 397
页数:5
相关论文
共 22 条
[1]  
Blumen SC, 1999, ANN NEUROL, V46, P115, DOI 10.1002/1531-8249(199907)46:1<115::AID-ANA17>3.0.CO
[2]  
2-O
[3]   Does size matter? [J].
Bouillon, T ;
Shafer, SL .
ANESTHESIOLOGY, 1998, 89 (03) :557-560
[4]   Oculopharyngeal muscular dystrophy [J].
Brais, B ;
Rouleau, GA ;
Bouchard, JP ;
Fardeau, M ;
Tomé, FMS .
SEMINARS IN NEUROLOGY, 1999, 19 (01) :59-66
[5]   Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy [J].
Brais, B ;
Bouchard, JP ;
Xie, YG ;
Rochefort, DL ;
Chrétien, N ;
Tomé, FMS ;
Lafrenière, RG ;
Rommens, JM ;
Uyama, E ;
Nohira, O ;
Blumen, S ;
Korcyn, AD ;
Heutink, P ;
Mathieu, J ;
Duranceau, A ;
Codère, F ;
Fardeau, M ;
Rouleau, GA .
NATURE GENETICS, 1998, 18 (02) :164-167
[6]   Safe use of mivacurium in oculopharyngeal muscular dystrophy [J].
Chun, R .
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 1998, 45 (11) :1134-1134
[7]  
DONATI F, 1988, Canadian Journal of Anaesthesia, V35, pS52
[8]   ANESTHETIC MANAGEMENT OF A PATIENT WITH FACIOSCAPULOHUMERAL MUSCULAR-DYSTROPHY [J].
DRESNER, DL ;
ALI, HH .
BRITISH JOURNAL OF ANAESTHESIA, 1989, 62 (03) :331-334
[9]  
DURANCEAU A, 1995, ESOPHAGEAL SURG, P389
[10]  
DURANCEAU AC, 1983, SURG CLIN N AM, V63, P825